Chief Executive Officer
“I am thrilled to lead an outstanding team that shares the critical mission to truly harness the power of immunotherapy for all patients with cancer.”
David Southwell is the President and Chief Executive Officer of TScan and also serves as a member of our board of directors. Previously, David served as President and Chief Executive Officer, and member of the board of directors of Inotek Pharmaceuticals Corporation from June 2014 until Inotek’s merger with Rocket Pharmaceuticals, Inc. in 2018. Prior to that, Mr. Southwell served as Executive Vice President, Chief Financial Officer of Human Genome Sciences, Inc. from 2010 until its merger with GlaxoSmithKline plc. in 2012 and as Executive Vice President and Chief Financial Officer of Sepracor Inc. from 1994 to 2008. Mr. Southwell is a member of the board of directors of PTC Therapeutics, Inc. and Rocket Pharmaceuticals, Inc.
Mr. Southwell received a B.A. from Rice University and an M.B.A. from the Tuck School at Dartmouth College, where he has served as head of the M.B.A. Advisory Board from 2008 to 2011 and served on the Board of Advisors from 2011 until 2020.
When away from the helm at TScan, David is an avid offshore racer on his sailboat “Alchemy.” He competes in both singlehanded and crewed events around the world.